Highlights Ceapro Inc.

Equities

CZO

CA1499071076

Delayed Toronto S.E. Other stock markets 14:30:00 16/05/2024 BST			5-day change	1st Jan Change
0.29 ^CAD	-1.69%		+13.73%	+52.63%

04-29	Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-29	Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-29	CI
Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-29	CI
Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions	03-28	MT
Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris	03-28	MT
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update	03-27	MT
Aeterna Zentaris Brief: Announcing Completion of Enrollment in Ongoing Pivotal DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency	03-27	MT
Aeterna Zentaris Brief: Reporting Q4 Net Loss of US$5.6 million, or $1.16 loss per common share	03-27	MT
Ceapro Brief: Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR Arrangement Agreement to Approve Merger of Equals to Create a Diversified Biopharmaceutical Co	02-26	MT
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create Diversified Biopharmaceutical Co	12-14	MT
Aeterna Zentaris and Ceapro Brief: Cos Announcing Merger of Equals to Create a Diversified Biopharmaceutical Co	12-14	MT
Ceapro Inc. Announces Dosing of First Patients In Phase 1-2a Study of Avenanthramides	12-13	MT
Ceapro Inc. Announces Commencement of Patient Dosing in its Phase 1-2a Study Evaluating its Product, Avenanthramides, for Potential Applications in Managing Conditions Related to Inflammation	12-13	CI
Ceapro Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-29	CI
Aeterna Zentaris Inc. entered into a definitive agreement to acquire Ceapro Inc. for CAD 20 million in a merger of equals transaction.	11-28	CI
Ceapro Inc. Initiates Phase 1-2a Study Assessing Avenanthramides For Potential Applications in Inflammation Based Diseases	11-27	MT
Ceapro Inc. Initiates Phase 1-2A Study Assessing Its Product Avenanthramides for Potential Applications in Inflammation Based Diseases	11-27	CI
Ceapro Inc. Announces the Signing of A Technical Collaboration with NATEX Prozesstechnologie Gmbh to Accelerate the Scale-Up of Its Proprietary PGX Technology Towards Commercial Level	11-07	CI
Ceapro Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	29/08/23	CI
Ceapro Extends International Supply and Distribution Agreement with German Provider of Active Ingredients, Symrise	25/08/23	MT
Ceapro Inc. Extends Exclusive International Supply and Distribution Agreement with Symrise	25/08/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ceapro Inc.

Equities

CZO

CA1499071076

Highlights

Filters